1. Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity : Evidence for Cross-Protection Against Oncogenic Types among Dutch STI Clinic Visitors
- Author
-
Woestenberg, PJ, King, AJ, van Benthem, BH, Donken, R, Leussink, S, van der Klis, FRM, de Melker, HE, van der Sande, M A J, Hoebe, CJ, Bogaards, JA, Adema, D, Buist-Arkema, R, Beerens, A, Luijt, D, Meijer, S, Schirm, J, Peeters, M, Rossen, JWA (John), Verbakel, H, Esch, PV, Verweij, J, Baltissen - van der Eijk, Annemiek, Huisman, RC, Kerkhof, C, Korff, MH, Schutten, M (Martin), Velzing, J, Verduyn-Lunel, F, Lakbiach, S, Rosmalen, PV, Schuurman, R (Rob), Abma, D, Adams, K, Bruisten, S, Linde, I, Oostvogel, P, Touwen, C, Vermeulen, W, Brink, A, Nelissen, J, Wolffs, P, Duijvendijk, N, Schneeberger, P, Poppel, MDV, Melchers, W, Poort, Y, Hooghiemstra, M, Huisman, H, Weel, J, Bosma, F, Geeraedts, F, Polman, I, Van Goor, P, Wolfhagen, M, De Mooij, C, Koolwijk, EV, Peters, M, Swanink, C, Tiemessen, R, Zwet, TV, Janssen, J, Pelsers, M, Waal, W, Aalfs, G, Kiewiet, J, Sanders, P, Buel-Bruins, HV, Bokhoven-Rombouts, CV, Cornelissen, P, Kersten, M, Ruitenbeek, CV, Molenaar, I, van Doorn, E, Masthoff, L, Pannekoek, E, Sigurdsson, V, Bugter, M, Götz, H, Linden, M, Mattijssen, M, Stam, J, Swaders, E, Groot, FD, Postma, F, Brouwers, E, Niekamp, A, Smit, M, Botraby, A, Bukasa, D, Haan, CD, Vliet, P, Taconis, T, Graas, MD, Hondelink, I, Kampman, C, Gelissen-Hansen, A, Koning, ID, Kruchten, HV, Pas, MVD, Fennema, H, Heijman, T, Hogewoning, A, Leeuwen, AV, Rooijen, MV, Neienhuijsen, F, Pelgrim, M, CCA - Cancer Treatment and quality of life, AII - Infectious diseases, Pathology, Epidemiology and Data Science, APH - Methodology, RS: CAPHRI - R4 - Health Inequities and Societal Participation, Med Microbiol, Infect Dis & Infect Prev, Promovendi PHPC, MUMC+: DA MMI Moleculaire dia (9), MUMC+: DA MMI Management (9), Microbes in Health and Disease (MHD), and Virology
- Subjects
Cervarix ,BROAD-SPECTRUM ,human papillomavirus vaccine ,INVASIVE CERVICAL-CANCER ,0302 clinical medicine ,INFECTION ,Immunology and Allergy ,030212 general & internal medicine ,human papillomavirus ,Papillomaviridae ,Netherlands ,Intraepithelial neoplasia ,education.field_of_study ,public health ,virus diseases ,HUMAN-PAPILLOMAVIRUS VACCINATION ,HPV-16/18 AS04-ADJUVANTED VACCINE ,female genital diseases and pregnancy complications ,Vaccination ,Treatment Outcome ,Infectious Diseases ,030220 oncology & carcinogenesis ,Viruses ,Vagina ,Vaginal swabs ,Female ,medicine.medical_specialty ,Adolescent ,Genotype ,Population ,Bivalent (genetics) ,Major Articles and Brief Reports ,Young Adult ,03 medical and health sciences ,SDG 3 - Good Health and Well-being ,Internal medicine ,PCR ASSAY ,Journal Article ,medicine ,Humans ,Papillomavirus Vaccines ,Human papillomavirus ,education ,OF-STUDY ANALYSIS ,vaccine effectiveness ,business.industry ,Papillomavirus Infections ,Type specific ,EFFICACY ,Cross-Sectional Studies ,INTRAEPITHELIAL NEOPLASIA ,BLIND PATRICIA TRIAL ,business - Abstract
In this cross-sectional study among vaccine-eligible female sexually transmitted infection clinic visitors, high vaccine effectiveness of the bivalent vaccine against the vaccine types HPV-16/18 was demonstrated and significant cross-protection against the nonvaccine high-risk HPV types 45, 35, 31, and 52., Background Observational postmarketing studies are important to assess vaccine effectiveness (VE). We estimated VE from the bivalent human papillomavirus (HPV) vaccine against HPV positivity of vaccine and nonvaccine types in a high-risk population. Methods We included all vaccine-eligible women from the PASSYON study, a biennial cross-sectional survey in Dutch sexually transmitted infection clinics. Vaginal swabs were analyzed using a polymerase chain reaction-based assay (SPF10-LiPA25) able to detect the 12 high-risk HPV (hrHPV) types 16/18/31/33/35/39/45/51/52/56/58/59. We compared hrHPV positivity between self-reported vaccinated (≥1 dose) and unvaccinated women, and estimated VE by a logistic mixed model. Results We included 1087 women of which 53% were hrHPV positive and 60% reported to be vaccinated. The adjusted pooled VE against HPV-16/18 was 89.9% (81.7%–94.4%). Moreover, we calculated significant VE against nonvaccine types HPV-45 (91%), HPV-35 (57%), HPV-31 (50%), and HPV-52 (37%). Among women who were offered vaccination 5/6 years ago, we estimated similar VE against HPV-16/18 (92%) and all hrHPV types (35%) compared to women who were offered vaccination
- Published
- 2018